martin ★★ Austria, 2010-06-25 21:50 (5433 d 05:50 ago) Posting: # 5563 Views: 9,180 |
|
Dear all! Motivated by a recent discussion with HS I would like start a thread regarding "rather" basic principles of pharmacokinetics:
Best regards Martin |
ElMaestro ★★★ Denmark, 2010-06-26 00:27 (5433 d 03:13 ago) @ martin Posting: # 5564 Views: 7,851 |
|
Dear Martin, I flipped my coin a few times:
I don't have all the answers, unfortunately. Best regards EM. — Pass or fail! ElMaestro |
martin ★★ Austria, 2010-06-26 10:13 (5432 d 17:27 ago) @ ElMaestro Posting: # 5566 Views: 7,781 |
|
Dear ElMaestro! Thank you very much for your answer and thought-provoking impulse. In my honest opinion, it is not possible to show linear kinetics (it's an assumption) in praxis but we may claim that a product exhibit sufficient dose-proportionality. I am trying to motivate my questions with the following example:
To answer this question, an estimate for the predominant half-life is needed as a product is practically eliminated from the body after 7 half-lifes have elapsed. Is it justified to summarize individual predominant half-lifes over all dose levels to get a single estimate and a confidence interval for the predominant half-life to answer the question above (having in mind that dose-proportionality does not necessarily imply "linear kinetics")? Best regards Martin |
ElMaestro ★★★ Denmark, 2010-06-26 13:43 (5432 d 13:57 ago) @ martin Posting: # 5567 Views: 7,715 |
|
Dear Martin, ❝ One question I am trying to answer is: How long does it take that the ❝ product is practically (i.e. 99.2% of steady state) eliminated from the ❝ body? "The body"...whose body? Yours? Mine? Subject number 51? I guess this is a population question, but I could be wrong. How about bootstrapping the whole thing 8 trillion billion times and extract 8 trillion billion halflives and construct a CI on that basis? If the sample you have reflects the distribution of the (relevant) population -whether normal or not- then I guess this approach would be difficult to reject from the regulatory side. Best regards EM. — Pass or fail! ElMaestro |
Ohlbe ★★★ France, 2010-06-28 00:07 (5431 d 03:33 ago) @ martin Posting: # 5568 Views: 7,803 |
|
Dear Martin, ❝ Is it justified to summarize individual predominant half-lifes over all ❝ dose levels to get a single estimate and a confidence interval for the ❝ predominant half-life You'll have to be aware of the limitations of the bioanalytical method you are using. If the LLOQ is not low enough you may not get a reliable estimate at the lower dose (not getting the terminal half-life but only seeing the distribution phase, or a mix of distribution and elimination). Regards Ohlbe — Regards Ohlbe |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2010-06-28 14:20 (5430 d 13:21 ago) @ martin Posting: # 5570 Views: 7,725 |
|
Dear Martin & all, did I get you right that you
nlme , because setting up the model, finding starting values and constraints may be a cumbersome task.If you don’t want to ‘do it at home only’, see regulatory requirements for Pop-PK: FDA 1999, EMA 2007.
— Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |